Trial Profile
The prospective study of nivolumab for advanced NSCLC patients with mild IIPs
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Feb 2020 Status changed from active, no longer recruiting to completed.
- 03 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2017 New trial record